As multiple Indian pharma companies race to launch cheaper semaglutide versions, doctors warn that while affordability could transform diabetes and obesity management, misuse, unrealistic expectations, and off-label cosmetic use remain real risks. Experts highlight spikes in patient enquiries, potential rebound weight gain, and the influence of celebrity transformations, stressing that the drug is effective, but not a magic fix, and must be paired with lifestyle changes and medical supervision.